Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCKET-ASCEND maintenance study of rocatinlimab in moderate-to-severe atopic dermatitis
2022-501587-17-00Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 41
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Rocatinlimab maintenance with Placebo maintenance (2 arms). Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Oct 2023; status: completed.
02
Drugs
rocatinlimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-501587-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501587-17-00.